Prostate Cancer

Lutetium Lu 177 vipivotide tetraxetan plus hormone therapy yielded rPFS and OS benefits vs hormone therapy alone in patients with PSMA-positive mHSPC.

The addition of ORIC-944 to an AR pathway inhibitor generated PSA responses in metastatic castration-resistant prostate cancer.

The top 5 OncLive videos of the week cover insights in HER2+ breast cancer, myeloma, pancreatic cancer, prostate cancer, and sarcoma.

FDA’s ODAC voted on therapeutic approaches in lymphoma, bladder, prostate, and myeloma, and more from OncLive this week.

Multiple experts on artificial intelligence in cancer care discuss its ever-expanding role in several areas of oncology.

The FDA’s ODAC voted 8 to 0 against the risk/benefit profile of talazoparib in combination with enzalutamide for patients with non-HRR–mutant mCRPC.

The top 5 OncLive videos of the week cover insights in ovarian cancer, prostate cancer, chronic lymphocytic leukemia, and breast cancer.

Jorge A. Garcia, MD, discusses the safety of Lu 177 vipivotide tetraxetan earlier in the treatment course for PSMA–positive mCRPC.

Evan Ya-Wen Yu, MD, discusses the PARP inhibitors that are available for the treatment of patients with mCRPC.

Tanya B. Dorff, MD, discusses the clinical characteristics and treatment preferences for initiating relugolix during prostate cancer treatment

Switzerland has approved piflufolastat (18F) as an imaging agent to detect PSMA-positive lesions in prostate cancer.

The Czech Republic’s State Institute for Drug Control has approved the Illuccix PSMA-PET imaging kit in adult patients with prostate cancer.

Challenges may arise as there could be unintended consequences on oncologic drug development, access, and innovation.

Ultra-low PSA responses were linked with prolonged rPFS and delayed times to mCRPC and PSA progression for patients with mHSPC treated with darolutamide.

The top 5 OncLive videos of the week cover insights in colorectal cancer, prostate cancer, myeloma, renal cell carcinoma, and urothelial carcinoma.

The FDA issues a CRL to a glioma imaging agent, an sBLA seeking approval of an epcoritamab triplet in follicular lymphoma is planned for submission, and more.

The phase 3 CAPItello-280 trial of capivasertib plus docetaxel/ADT in metastatic castration-resistant prostate cancer is being discontinued.

Darolutamide plus ADT improved rPFS in Black patients with metastatic hormone-sensitive prostate cancer treated in ARANOTE.

The majority of patients with prostate cancer treated with an enzalutamide or leuprolide acetate regimen recovered their testosterone levels.

Patients with mCRPC enrolled in the phase 3 TALAPRO-2 trial harboring TMPRSS2-ERG fusions in ctDNA had a distinct tumor molecular profile vs those without.

Talazoparib plus enzalutamide improved rPFS vs placebo plus enzalutamide in patients with mCRPC with or without AR alterations.

No complete or partial pathologic responses were achieved with neoadjuvant niraparib in patients with DDR-deficient prostate cancer following surgery.

Experts highlight the top presentations to watch for at the 2025 AUA Annual Meeting.

Evan Y. Yu, MD, discusses the clinical evolution of radiopharmaceuticals for patients with mCRPC and how PSMA PET may evolve to monitor treatment response.

Nataliya Mar, MD, discusses clinical considerations when selecting between the wide range of androgen receptor pathway inhibitors in prostate cancer.